Wednesday, March 11, 2020 5:59:24 PM
In addition to receiving national attention, they have:
1) a medication that has known human safety
2) demonstrated "signal" or treatment effect (positive data) for the most serious form of influenza which results in a systemic inflammatory response with resultant acute respiratory distress syndrome that is of the same kind that the coronavirus (COVID) causes.
Translation: If it works for severe influenza virus related lung disease, it is almost certain to work for coronavirus related lung disease.
3) the patents and "control" of their drug
4) Millions of $ in cash in their pocket (based on the news release and BioPub info they provided)
5) Most importantly drug that is ready to be used!!!...
6) They could start their trial tomorrow.
7) When they announce a CRO that will conduct the trial, this will immediately be in the dollars range. There's companies trading in that range with FAR less potential.
Big pharma could swoop in and make offers here, but I have a feeling these guys realize that if they get positive results in the next few weeks that the payout is going to be exponential...
Congrats to everyone who has found this before it shoots to the dollars.
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM